NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company
globenewswire.com
news
2022-10-21 00:00:00

PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ('NeuBase' or the 'Company'), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced a research agreement with a Top 10 Global Healthcare company ('Healthcare Company') (based on 2021 revenues). For this research, the Healthcare Company will evaluate NeuBase's PATrOL™ technology for three monogenic genetic diseases.
